{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:14:08Z","timestamp":1758478448700},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T00:00:00Z","timestamp":1416873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A serologic hallmark of autoimmune hepatitis (AIH) type 1 are anti\u2010smooth muscle autoantibodies (ASMA) with specificity for filamentous actin (F\u2010actin; AAA (anti\u2010actin antibodies)), traditionally detected by indirect immunofluorescence (IFT) using rat liver, kidney, and stomach tissue sections as substrates. However, IFT is a subjective method requiring an experienced investigator. Therefore, a more objective technique for the detection of AAA may be a helpful diagnostic tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a retrospective study with cross\u2010sectional design, we evaluated AAA detected by an enzyme immunodot blot (IDB; Liver5 IgG BlueDot, D\u2010tek, Mons, Belgium). Serum samples of patients with AIH type 1 (<jats:italic>n<\/jats:italic> = 47) and specified controls (<jats:italic>n<\/jats:italic> = 142) were included. For comparison, standard IFT was applied to rat LKS (liver, kidney, stomach) triple tissue sections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IDB readings were done by two independent investigators (92% concordance). The diagnostic sensitivity of the AAA\u2010IDB was 70%, compared to 51% of AAA\u2010IFT (n.s.). The diagnostic specificity of AAA\u2010IDB was significantly lower compared to AAA\u2010IFT (76% vs. 94%; <jats:italic>P<\/jats:italic> &lt; 0.0005). Correspondingly, the positive predictive value (49% vs. 75%; <jats:italic>P<\/jats:italic> &lt; 0.05) and positive likelihood ratio (2.9 vs. 8.5) differed significantly. Neither prescreening for ANA or ASMA, nor the exclusion of infectious hepatopathies resulted in a significantly better diagnostic performance of the IDB.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to standard IFT, testing for AAA via IDB did not result in a significantly better diagnostic performance for AIH type 1. A blot with higher antigen binding specificity may be more functional.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcla.21825","type":"journal-article","created":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T19:31:41Z","timestamp":1416943901000},"page":"123-129","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostic Performance of an Anti\u2010Actin Autoantibody Binding Enzyme Immunodot Blot in Autoimmune Hepatitis Type 1"],"prefix":"10.1002","volume":"30","author":[{"given":"Heiko","family":"Schotte","sequence":"first","affiliation":[{"name":"Niels\u2010Stensen\u2010Kliniken  Osnabr\u00fcck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Willeke","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik D Universit\u00e4tsklinikum M\u00fcnster  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Schmalhorst","sequence":"additional","affiliation":[{"name":"Centrum f\u00fcr Laboratoriumsmedizin Universit\u00e4tsklinikum M\u00fcnster  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Schl\u00fcter","sequence":"additional","affiliation":[{"name":"Centrum f\u00fcr Laboratoriumsmedizin Universit\u00e4tsklinikum M\u00fcnster  Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00021-1"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050408"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3301"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280210"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1740-2557-4-3"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.08.043"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840070626"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90160-E"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.29.5.403"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00830.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2005.027367"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20274"},{"key":"e_1_2_6_17_1","unstructured":"D\u2010tek sa Mons Belgium.Liver5 IgG BlueDot\/LISD\u201024: Instructions for use. Available at:http:\/\/www.d\u2010tek.be\/dot.php. Accessed in May 29 2014."},{"key":"e_1_2_6_18_1","unstructured":"BioSystems S.A. Barcelona Spain.Autoantibodies\u2010RL\/RK\/RS: Instructions of use. Available at:http:\/\/www.biosystems.es\/products\/DIAGNOSTICS\/Autoimmunity\/IMMUNOFLUORESCENCE\/Tissues\/AUTOANTIBODIES\u2010RL\u223dRK\u223dRS_%28AA\u2010RL\u223dRK\u223dRS%29. Accessed in May 29 2014."},{"key":"e_1_2_6_19_1","unstructured":"Hemagen Columbia MD USA.VIRGO ANA\/Hep\u20102 IgG determination kits: Principle of the test. Available at:http:\/\/www.hemagen.com\/product_inserts\/anakb8901002_K.pdf. Accessed in May 29 2014."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510330081039"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.10040"},{"key":"e_1_2_6_22_1","first-page":"611","article-title":"ELISA assay for IgG autoantibody to G\u2010actin: Comparison of chronic active hepatitis and acute viral hepatitis","volume":"51","author":"Bretherton L","year":"1983","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(90)90291-3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.028"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/08916930701619896"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(92)90068-Y"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.21825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.21825","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.21825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T22:30:53Z","timestamp":1694298653000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.21825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,25]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/jcla.21825"],"URL":"https:\/\/doi.org\/10.1002\/jcla.21825","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,25]]}}}